Aussie court tosses Lipitor suit against Pfizer; Novartis nabs FDA approval for multiple myeloma med;

> Pfizer's ($PFE) strategy of offering steep Lipitor rebates as the drug's patent neared expiration didn't constitute anticompetitive conduct, an Australian judge said, tossing a lawsuit filed by the Australian Competition and Consumer Commission. Report (sub. req.)

> Novartis ($NVS) won FDA approval for its multiple myeloma drug Farydak, as a third line treatment. Report

> The global cancer drug market is expected to hit $111 billion by 2020, new market research shows. Report

> Hospira ($HSP) and Celltrion launched their biosimilar versions of Remicade in Europe, where the brand earned €2 billion last year. Report (reg. req.)

And Finally... Preventive treatment with an HIV drug reduced infection by 86% in gay men at high risk of contracting the disease. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.